Prevail and Alector both claim victory in arbitration over scientist-CEO, telling divergent tales of confidential hearings
At 7 am Monday, Prevail Therapeutics announced their CEO “decisively” won a year-plus-long arbitration battle over trade secrets with his old company, the neurodegeneration rival Alector. Forty four minutes later, Alector put out a press release saying that the arbitrator found in Alector’s favor and against Prevail’s CEO.
It was the second and perhaps final twist in an unusual case that centered on Asa Abeliovich, a former tenured Columbia professor and neurodegeneration luminary, and the intellectual property inside the two high-profile biotechs he helped launch. Drawing from a confidential decision, each side claimed victory, telling overlapping but distinctly divergent tales of where an arbitrator ruled on a man at the center of both companies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
